UNICA IRIS Institutional Research Information System

LA NASA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 282.396
NA - Nord America 20.681
AS - Asia 8.495
SA - Sud America 1.630
AF - Africa 205
OC - Oceania 98
Continente sconosciuto - Info sul continente non disponibili 8
Totale 313.513
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 272.714
US - Stati Uniti d'America 20.355
CN - Cina 3.313
NL - Olanda 3.297
SG - Singapore 3.226
UA - Ucraina 1.837
SE - Svezia 1.495
BR - Brasile 1.333
DE - Germania 827
GB - Regno Unito 689
FI - Finlandia 598
VN - Vietnam 486
KR - Corea 316
FR - Francia 298
IN - India 246
CA - Canada 195
HK - Hong Kong 150
JP - Giappone 116
AR - Argentina 108
PL - Polonia 98
MX - Messico 91
IE - Irlanda 87
AU - Australia 84
RU - Federazione Russa 79
TR - Turchia 79
AT - Austria 77
BD - Bangladesh 69
IR - Iran 67
ZA - Sudafrica 67
IQ - Iraq 66
ES - Italia 57
PK - Pakistan 47
EC - Ecuador 46
ID - Indonesia 45
CO - Colombia 38
EG - Egitto 38
BE - Belgio 36
SA - Arabia Saudita 36
CZ - Repubblica Ceca 32
MY - Malesia 31
MA - Marocco 30
LT - Lituania 25
CH - Svizzera 24
IL - Israele 24
PH - Filippine 23
UZ - Uzbekistan 23
VE - Venezuela 23
CL - Cile 20
DK - Danimarca 20
AE - Emirati Arabi Uniti 18
PE - Perù 18
PY - Paraguay 15
RO - Romania 15
TH - Thailandia 15
HU - Ungheria 13
KZ - Kazakistan 13
TW - Taiwan 13
UY - Uruguay 13
MU - Mauritius 12
NZ - Nuova Zelanda 12
PT - Portogallo 12
JO - Giordania 11
NP - Nepal 11
BO - Bolivia 10
IS - Islanda 10
KE - Kenya 10
EU - Europa 8
SD - Sudan 8
SK - Slovacchia (Repubblica Slovacca) 8
DO - Repubblica Dominicana 7
DZ - Algeria 7
GR - Grecia 7
NO - Norvegia 7
TZ - Tanzania 7
AZ - Azerbaigian 6
BG - Bulgaria 6
ET - Etiopia 6
JE - Jersey 6
JM - Giamaica 6
LB - Libano 6
PS - Palestinian Territory 6
OM - Oman 5
PA - Panama 5
PR - Porto Rico 5
QA - Qatar 5
AM - Armenia 4
AO - Angola 4
BY - Bielorussia 4
CY - Cipro 4
HN - Honduras 4
LU - Lussemburgo 4
AL - Albania 3
CI - Costa d'Avorio 3
GE - Georgia 3
GY - Guiana 3
KG - Kirghizistan 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
Totale 313.472
Salva come PNG Salva come JPEG
Città #
Cagliari 262.874
Uta 7.753
Amsterdam 3.180
Fairfield 1.949
Ashburn 1.725
Woodbridge 1.623
Singapore 1.514
Chandler 1.470
Boardman 1.231
Dallas 1.132
Houston 1.053
Ann Arbor 1.015
Jacksonville 945
Wilmington 854
Nyköping 847
Seattle 758
Beijing 683
Cambridge 668
New York 447
Hefei 404
Los Angeles 392
Nanjing 315
Boston 303
Helsinki 282
Seoul 246
Santa Clara 227
Dearborn 211
Munich 197
Milan 192
Buffalo 169
Shanghai 164
Dong Ket 150
Rome 149
San Diego 140
Ho Chi Minh City 122
The Dalles 120
São Paulo 117
Hong Kong 111
Shenyang 101
Hebei 90
Changsha 87
Guangzhou 81
Nanchang 81
Redondo Beach 81
Toronto 79
Verona 79
Tianjin 75
London 74
Redwood City 73
Atlanta 68
Rio de Janeiro 67
Warsaw 66
Nuremberg 65
Hanoi 63
Jiaxing 63
Orange 61
Chicago 59
Menlo Park 59
Washington 55
Council Bluffs 54
Frankfurt am Main 53
Mountain View 51
Dublin 50
Norwalk 50
Sassari 49
Tokyo 49
Phoenix 48
Pune 48
Montreal 43
Vienna 43
Brooklyn 40
Denver 37
Stockholm 37
Incheon 36
Jinan 36
Sydney 35
Brussels 34
Ningbo 31
Chennai 29
Auburn Hills 28
Turku 28
Redmond 27
Mumbai 26
Zhengzhou 26
Ankara 25
Brasília 25
Falls Church 25
Johannesburg 25
San Francisco 25
Baghdad 24
San Jose 24
Columbus 22
Tashkent 22
Manchester 21
Mexico City 20
Berlin 19
Borås 19
Brandenburg 19
Curitiba 19
Porto Alegre 19
Totale 298.600
Salva come PNG Salva come JPEG
Nome #
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.501
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.555
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 3.399
The impact of NOD2/CARD15 SNPs on the severe gastrointestinal GVHD following allogeneic Stem Cell Transplantation in Sardinia population 3.391
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.347
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.341
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.317
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 3.282
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.276
Long-term follow-up more than 10 years after HSCT: a monocentric experience 3.269
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.186
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 3.020
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.865
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.761
Ruolo del trapianto allogenico nelle talassemie 2.718
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.710
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.683
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.564
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.542
In vitro ovine articular chondrocyte proliferation: experiments and modelling 2.515
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.487
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.238
Experimental analysis and modelling of in vitro proliferation of mesenchymal stem cells 2.193
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.186
Health related quality of life in patients with onco-hematological diseases 2.185
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.155
Killer-cell immunoglobulin-like receptors (KIR) and HLA-class I heavy chains in ankylosing spondylitis 2.127
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.087
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 2.075
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.074
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 2.019
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 1.944
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.930
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09 1.925
Ruxolitinib therapy and telomere length in myelofibrosis 1.913
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.910
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.905
Experimental analysis and modeling of in vitro mesenchymal stem cells proliferation 1.880
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.852
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.812
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.801
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.786
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.783
null 1.759
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.733
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.692
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.636
Acute basophilic leukemia with U2AF1 mutation 1.555
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.552
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.548
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.530
Unrelated bone marrow transplantation in Thalassemia. The experience of the Italian Bone Marrow transplant Group (GITMO) 1.529
T cell tyrosine phosphorylation response to transient redox stress 1.522
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.514
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.509
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.502
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.463
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.451
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.434
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.431
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party 1.430
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.424
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.419
null 1.419
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.418
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.407
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 1.368
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.363
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.351
Improved outcomes With retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial 1.330
The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study 1.329
A simulated case of chronic myeloid leukemia: the growing risk of Munchausen’s Syndrome by internet 1.296
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.289
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.287
Immunological deregulation in classic hodgkin lymphoma 1.280
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.272
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.271
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.268
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major 1.256
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 1.197
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 1.192
Could there be Haemodynamic Stress Effects on Pro-Inflammatory CD14+CD16+ Monocytes during Convective-Diffusive Treatments? A Prospective Randomized Controlled Trial 1.176
Multiple myeloma treatment in real-world clinical practice: Results of a prospective, multinational, noninterventional study 1.173
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 1.169
Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation 1.166
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.163
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 1.161
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination 1.157
Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial 1.146
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 1.142
null 1.138
Dasatinib first-line: multicentric Italian experience outside clinical trials 1.135
Immunohistochemical findings in the lungs of COVID-19 subjects: Evidence of surfactant dysregulation 1.134
null 1.128
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 1.124
null 1.110
Expression of l1 cell adhesion molecule (l1cam) in extracellular vesicles in the human spinal cord during development 1.105
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated haematopoietic stem cell transplantation 1.102
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 1.066
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 1.060
Totale 184.290
Salva come PNG Salva come JPEG
Categoria #
all - tutte 444.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 444.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132.335 0 0 0 0 0 8.978 7.127 4.776 1.513 4.260 3.424 2.257
2021/202217.937 1.650 1.598 760 1.108 1.369 1.078 857 1.108 1.518 2.163 2.377 2.351
2022/202325.815 2.001 2.970 2.705 1.991 2.030 2.703 1.279 3.292 1.629 1.580 2.425 1.210
2023/202429.541 1.598 1.200 1.519 2.189 2.610 4.937 3.738 2.052 1.522 2.385 2.983 2.808
2024/202558.229 9.818 10.782 9.877 6.931 3.620 6.636 3.175 487 1.063 3.964 829 1.047
2025/20268.759 1.362 955 2.691 1.967 1.543 241 0 0 0 0 0 0
Totale 314.598